Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088837 | 0.95 | MAPT (0.79) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7402196 | 0.90 | MAPT (0.77) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| Methylparaben SCHEMBL31086508 | 0.89 | MAPT (0.70) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7314671 | 0.89 | MAPT (0.74) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL1794811 | 0.89 | MAPT (0.74) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL6835771 | 0.88 | MAPT (0.79) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7321276 | 0.87 | MAPT (0.72) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL7323935 | 0.87 | MAPT (0.72) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL4815928 | 0.87 | MAPT (0.77) | MAPTRAB9AL3MBTL1TDP1CA1 | |
| SCHEMBL23986235 | 0.86 | MAPT (0.66) | MAPTRAB9AL3MBTL1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111340-A1 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-08-15 | — | — | US | disclosed |
| WO-2002040461-A2 | AMINOALKOXYBIPHENYL CARBOXAMIDES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-23 | — | — | WO | disclosed |
| US-6316475-B1 | TREATMENT OF CANCER, ASTHMA, HEART DISEASES, SEIZURES, INFLAMMATION | ABBOTT LABORATORIES | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111340-A1 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | MAPT 3425/4885RAB9A 1967/4885L3MBTL1 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.